Nature Communications (Feb 2023)
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
- James Logue,
- Robert M. Johnson,
- Nita Patel,
- Bin Zhou,
- Sonia Maciejewski,
- Bryant Foreman,
- Haixia Zhou,
- Alyse D. Portnoff,
- Jing-Hui Tian,
- Asma Rehman,
- Marisa E. McGrath,
- Robert E. Haupt,
- Stuart M. Weston,
- Lauren Baracco,
- Holly Hammond,
- Mimi Guebre-Xabier,
- Carly Dillen,
- M. Madhangi,
- Ann M. Greene,
- Michael J. Massare,
- Greg M. Glenn,
- Gale Smith,
- Matthew B. Frieman
Affiliations
- James Logue
- The Department of Microbiology and Immunology, The University of Maryland School of Medicine
- Robert M. Johnson
- The Department of Microbiology and Immunology, The University of Maryland School of Medicine
- Nita Patel
- Novavax, Inc
- Bin Zhou
- Novavax, Inc
- Sonia Maciejewski
- Novavax, Inc
- Bryant Foreman
- Novavax, Inc
- Haixia Zhou
- Novavax, Inc
- Alyse D. Portnoff
- Novavax, Inc
- Jing-Hui Tian
- Novavax, Inc
- Asma Rehman
- Novavax, Inc
- Marisa E. McGrath
- The Department of Microbiology and Immunology, The University of Maryland School of Medicine
- Robert E. Haupt
- The Department of Microbiology and Immunology, The University of Maryland School of Medicine
- Stuart M. Weston
- The Department of Microbiology and Immunology, The University of Maryland School of Medicine
- Lauren Baracco
- The Department of Microbiology and Immunology, The University of Maryland School of Medicine
- Holly Hammond
- The Department of Microbiology and Immunology, The University of Maryland School of Medicine
- Mimi Guebre-Xabier
- Novavax, Inc
- Carly Dillen
- The Department of Microbiology and Immunology, The University of Maryland School of Medicine
- M. Madhangi
- Novavax, Inc
- Ann M. Greene
- Novavax, Inc
- Michael J. Massare
- Novavax, Inc
- Greg M. Glenn
- Novavax, Inc
- Gale Smith
- Novavax, Inc
- Matthew B. Frieman
- The Department of Microbiology and Immunology, The University of Maryland School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-35606-6
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 16
Abstract
Current SARS-CoV-2 variants evade immune responses induced by approved vaccines. In this study, the authors find that a recombinant prefusion-stabilized Beta spike protein vaccine confers broad neutralization capacity in mice and non-human primates as well as protective antibody and immune memory responses.
